Please assess the completion status of the following clinical trial:

Trial Title: Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30+ years~* Hypertriglyceridemia (150-400 mg/dl)~* Statin use for at least six months at the time of screening~* Type 2 diabetes treated with diet and/or oral hypoglycemic agents diagnosed 1+ year~* Ability to provide informed consent and provide blood samples~* Willingness to abstain from fish oil, EPA, over the counter niacin, and other omega-3 fatty acid supplements during the study period (12 weeks)~* Ability to travel to the study site at Brigham and Women's Hospital for 3 study visits~* Reactive hyperemia index (RHI) of ≤ 2.0~Exclusion Criteria:~* Eating disorder or heavy drinkers~* Treatment with chronic prescription pharmacotherapy for metabolic or cardiovascular disease management or risk factor modification~* Pregnant or lactating women~* Statin use \<6 months at the time of screening~* Allergy to EPA, fish oil, or other omega-3 fatty acids~* Current use of insulin, cyclophosphamide, estrogen, fibrates, niacin, hormone replacement therapy, testosterone, oral contraceptives, growth hormones, insulin-like growth factor-1, and other systemic steroids.~* Inability to provide informed consent or blood samples~* History or prevalent diagnosis of cancer, asthma, kidney insufficiency, stroke, seizures, allergic disorders, or congestive heart failure~* Diagnosis of diabetes \< 1 year prior to enrollment~* Intention to move out of greater Boston area within one year~* Current use of omega-3 supplements, fish oil, or \>2 servings of fish per week~* Bleeding disorder or uncontrolled endocrine (i.e., thyroid) or metabolic disorders~* Treatment with blood thinning drugs (i.e. warfarin and clopidogrel)~* Major surgical operation 3 months before or after screening~* Organ transplantation~* Current participation in another trial or plan to do so during the study~* Inability to give informed consent or to travel to the study center at Brigham and Women's Hospital~* RHI of \>2.0~* Triglycerides \<150 mg/dl or \>400 mg/dl~* Body mass index of 40+ kg/m2

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EPA arm (Type: EXPERIMENTAL): EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
- Control (Type: NO_INTERVENTION): Control group will not receive EPA

Based on this trial design, predict the completion outcome and termination type (if applicable).